Viridian Therapeutics, Inc. reported $71M of revenue over the trailing twelve months, +23220% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $71M (to Q2 2026). Net income: −$387M, trailing twelve months to Q2 2026. Free cash flow: −$335M, trailing twelve months to Q2 2026. Operating margin: −54975%, trailing twelve months to Q2 2026.

VRDNViridian Therapeutics, Inc.

Healthcare

$18.67-3.9% 1Y

$18.67

$13.3052 weeks$33.78

VRDN as reported

Viridian Therapeutics, Inc. reported $71M of revenue over the trailing twelve months, +23220% on the year before. 10 reported series are charted on this page, each one as filed.

$71M

Revenue, trailing twelve months · to Q2 2026 · +23220% against the twelve months before

Net income: −$387M
Net income · +12% year on year · trailing twelve months to Q2 2026
Free cash flow: −$335M
Free cash flow · +8.2% year on year · trailing twelve months to Q2 2026
Operating margin: −54975%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for VRDN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$71M	+23220%	Q2 2026
Net income	−$387M	+12%	Q2 2026
EPS	−$4.30	n/a	Q3 2024 · 7 quarters behind
Gross margin	35%	n/a	Q4 2016 · 38 quarters behind
Operating margin	−54975%	n/a	Q2 2026
Net margin	−52596%	n/a	Q2 2026
ROE	−56%	n/a	Q2 2026
ROA	−43%	n/a	Q2 2026
ROIC	884%	n/a	Q3 2025
Free cash flow	−$335M	+8.2%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.